What is forming beneath the surface is a topology of differential velocity. Ketamine accelerates — it already escaped the scheduling constraint and is now expanding laterally into pediatric and oncology populations, following the same clinical logic that drove its adult depression adoption. MDMA slows — not because the science failed, but because the regulatory architecture is performing exactly as designed when it encounters data quality concerns it cannot bracket. Psilocybin holds a middle position: the neuroplasticity biomarker publications predicted for 2026, with the Hopkins pipeline running at full capacity and psilocybin registering 13x signal frequency in today's data, will not unlock scheduling but will deepen the mechanistic case that makes future approval harder to deny. The highest trajectory genuinely available from here is not a sudden rupture but a layered maturation — the biomarker evidence accumulating, the MDMA file being rebuilt with therapist fidelity documentation rigorous enough to survive a second advisory committee, the ketamine safety cohort in pediatrics generating the longitudinal data that will define the neurodevelopmental boundary. The path is slower than advocates want. It is also more durable than the path that rushed.
The people living inside this slowness are not abstractions. Veterans who sought ibogaine treatment in Mexico or Portugal because no domestic option existed are watching Congress debate NDAA waiver language while the DEA prepares its formal opposition, citing diversion risk — opposition that is procedurally predictable but lands like a door closing in a dark hallway. Families of adolescents cycling through failed antidepressant protocols are watching pediatric ketamine trials open with cautious hope and genuine fear simultaneously, because the neurodevelopmental unknowns are real and the suffering is also real. Patients who enrolled in MAPS trials and experienced something that changed them are reading headlines about another probable delay and feeling the gap between what they know happened in their bodies and what the regulatory record is able to hold. What becomes possible for them — the highest timeline — is not a fast approval secured by political pressure, but a thorough one that cannot be reversed: a dossier so complete that when the door finally opens, it stays open.
OOTW doesn't sell products. It delivers transmissions — a daily reminder that the intelligence which created us is still creating, still calling us forward.
The intelligence that created you is still creating.
82%
Ketamine becomes the dominant billable psychedelic treatment by 2027
Ketamine and esketamine (a variant) will account for more patient visits and insurance billing than all other psychedelic treatments combined through mid-2027. This matters because esketamine already has FDA (the U.S. drug regulator) approval and insurance coverage, while MDMA approval is stalled and psilocybin has no federal approval yet. Thousands of IV ketamine clinics already operate across the U.S., giving ketamine an enormous head start.
→ Ketamine will dominate psychedelic clinical care through 2027 simply because it already has FDA approval and insurance coverage.
Resolves: 2027-09-30 · USA
RESEARCH
the precise call ▾
Ketamine/esketamine accounts for more billable psychedelic-adjacent clinical encounters in U.S. healthcare settings than all other psychedelic compounds combined through Q3 2027, per published utilization data.. Esketamine (Spravato) has FDA approval, established insurance reimbursement pathways, and a multi-year head start. MDMA approval is stalled; psilocybin has no federal approval. IV ketamine clinics number in the thousands. No single competitor can close this gap in 12-18 months. Resolution requires a
73%
Scientists publish psilocybin brain-healing findings in top journals
At least two high-impact scientific journals (Nature Medicine, JAMA Psychiatry, or similar tier-1 publications) will publish peer-reviewed studies showing how psilocybin physically reshapes the brain in ways that reduce depression. These studies will measure specific brain markers like growth factors and brain cell connections that demonstrate psilocybin's healing mechanism. This matters because concrete biological proof moves psilocybin from anecdotal to scientifically grounded treatment.
→ Top scientific journals will publish concrete evidence of how psilocybin physically heals depressed brains.
Resolves: 2026-12-31 · Global
RESEARCH
the precise call ▾
At least 2 peer-reviewed publications in journals with impact factor ≥10 report novel neuroplasticity biomarkers associated with psilocybin's antidepressant effect, published before 2027-01-01.. Johns Hopkins, Imperial College London, and UC Davis all have psilocybin neuroplasticity manuscripts in late-stage review or accepted-pending-publication as of mid-2026. BDNF, dendritic spine density, and default mode network connectivity are active biomarker targets with clear measurable endpoints.
71%
U.S. medical centers launch ketamine trials for suicidal youth
At least three major U.S. academic hospitals will start FDA (U.S. drug regulator) approved clinical trials testing ketamine for young people who are suicidal or resistant to antidepressants by the end of 2026. This matters because ketamine already has FDA approval for adults, which makes it far easier for hospitals to test in children. Suicidal youth represent a genuine emergency that has bipartisan political support, so hospitals have strong incentive to move fast.
→ Three or more U.S. academic hospitals will launch ketamine trials for suicidal teenagers by end of 2026.
Resolves: 2026-12-31 · USA
RESEARCH
the precise call ▾
At least 3 new IRB-approved clinical trials studying ketamine for pediatric suicidal ideation or treatment-resistant depression open enrollment at U.S. academic medical centers before 2027-01-01.. Pediatric suicidal ideation represents a genuine unmet need with bipartisan political cover. Ketamine is already FDA-approved (esketamine for adults), lowering IRB risk threshold for pediatric extension studies. A positive pilot RCT result (per today's intelligence) typically generates 3-5 follow-on
74%
DEA formally opposes ibogaine legal exemption in Congress
The DEA (U.S. Drug Enforcement Administration) will file an official public objection if Congress tries to carve out ibogaine as a legal exception to Schedule I drug rules in the 2027 defense bill. This matters because ibogaine is a Schedule I drug with abuse risk, and the DEA has a legal duty to oppose scheduling exemptions. The agency opposed similar exemptions for kratom and will likely do the same here.
→ The DEA will publicly oppose any congressional attempt to create a legal ibogaine exemption.
Resolves: 2026-10-01 · USA
REGULATORY
the precise call ▾
DEA files formal public comment opposing any NDAA 2027 ibogaine scheduling waiver language, citing diversion risk and insufficient Schedule I exception precedent.. DEA has statutory obligation to comment on scheduling-adjacent legislative proposals affecting Schedule I substances. The agency opposed the kratom scheduling exemption and has consistently resisted carve-outs. No credible counterargument exists for DEA staying silent on a Schedule I waiver embedded
72%
FDA rejects MDMA therapy approval again in late 2026
The FDA will issue a second rejection letter (called a Complete Response Letter) to the company seeking MDMA approval, likely by the end of 2026. The FDA's concern will focus on whether therapists actually stuck to the treatment protocol and whether patients could tell they were receiving real MDMA versus placebo. This delays MDMA approval to at least 2028. This matters because it signals the FDA's bar for approval is higher than initially thought—the agency wants ironclad proof of proper therapist conduct.
→ The FDA will reject MDMA approval again in late 2026, pushing legal access to 2028 or later.
Resolves: 2026-12-31 · USA
REGULATORY
the precise call ▾
FDA issues formal Complete Response Letter on MDMA NDA resubmission by Q4 2026, citing therapist fidelity data gaps — approval pushed to 2028 at earliest.. Lykos Therapeutics received a CRL in August 2024. Any resubmission triggers a 6-month FDA review clock. Persistent gaps in therapist conduct monitoring and unblinding contamination documented in the 2024 AdCom make a second CRL the base case. Resolution is binary and public: either a CRL is issued o